Biosense Webster Inc.’s Thermocool SmartTouch is the first therapeutic catheter available in the U.S. that enables direct and real-time measurement of contact force during catheter ablation procedures for drug-resistant paroxysmal atrial fibrillation, the firm announced Feb. 25. FDA approved a PMA supplement for the device indicated to treat atrial fibrillation and sustained monomorphic ischemic ventricular tachycardia and Type I atrial flutter, on Feb. 11, according to FDA’s PMA database
.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?